Lilly's sales growth undone by Zyprexa probes
This article was originally published in Scrip
Executive Summary
Lillyswung into a third quarter loss after the company recorded charges of nearly $1.5 billion relating to US federal probes into Zyprexa (olanzapine). Although sales rose by 14% to $5.2 billion, the investigation vitiated earnings and pushed Lilly towards a net loss of $465.6 million.